Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine analogues.

J R Jeffery1

  • 1Transplant Research Group, Health Sciences Centre, Winnipeg, Manitoba, Canada.

Clinical Biochemistry
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Cyclosporine G (CsG), a promising analogue of cyclosporine A (CsA), shows variable immunosuppressive and toxic effects in animals. Human studies are needed to compare CsG and CsA safety and efficacy for transplantation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney transplantation outcomes in Canadian aboriginals.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2006
Same author

The urine protein to creatinine ratio (P/C) as a predictor of 24-hour urine protein excretion in renal transplant patients.

Transplantation·2001
Same author

Increased levels of GALbeta1-4GLCNACalpha2-6 sialyltransferase pretransplant predict delayed graft function in kidney transplant recipients.

Transplantation·2001
Same author

Does subclinical rejection contribute to chronic rejection in renal transplant patients?

Clinical transplantation·2000
Same author

Immune-activation gene expression in clinically stable renal allograft biopsies: molecular evidence for subclinical rejection.

Transplantation·1999
Same author

Protocol biopsies in renal transplantation: research tool or clinically useful?

Current opinion in nephrology and hypertension·1998
Same journal

Analytical outlier rates for Roche fifth generation cardiac troponin T stat using biotin sensitive and insensitive reagent lots.

Clinical biochemistry·2026
Same journal

Evaluation of hemoglobin interference thresholds for chemical urinalysis panels.

Clinical biochemistry·2026
Same journal

Integrated genomic and biochemical diagnosis of a novel homozygous start-loss variant in AKR1D1 associated with neonatal cholestasis.

Clinical biochemistry·2026
Same journal

Agreement between POC glucose meters and blood gas analyzers varies across ICU patient populations.

Clinical biochemistry·2026
Same journal

From variability to value: Advancing vancomycin therapeutic drug monitoring toward decision-grade practice through commutability-informed external quality assessment and uncertainty-aware reporting.

Clinical biochemistry·2026
Same journal

Response to the letter to the editor: From variability to value: Advancing vancomycin therapeutic drug monitoring toward decision-grade practice through commutability-informed external quality assessment and uncertainty-aware reporting.

Clinical biochemistry·2026
See all related articles

Area of Science:

  • Immunopharmacology
  • Nephrology
  • Transplantation Medicine

Background:

  • Cyclosporine A (CsA) is a benchmark immunosuppressive agent.
  • Numerous CsA analogues have been synthesized to improve safety and efficacy.
  • Cyclosporine G (CsG), with a norvaline substitution at position 2, is a key analogue.

Purpose of the Study:

  • To evaluate the immunosuppressive potential and nephrotoxicity of Cyclosporine G (CsG) compared to Cyclosporine A (CsA).
  • To investigate structure-activity relationships of CsA analogues.
  • To determine the clinical relevance of CsG in immunosuppression.

Main Methods:

  • Comparative analysis of CsA and CsG in animal models.
  • Assessment of immunosuppressive activity.

Related Experiment Videos

  • Evaluation of nephrotoxicity profiles.

    • Main Results:

    • Animal studies yielded conflicting results regarding CsG's immunosuppressive efficacy and nephrotoxicity.
    • Evidence suggests significant species and strain differences in CsG metabolism and sensitivity.
    • No analogue has matched the safety and efficacy profile of CsA to date.

    Conclusions:

    • The variable outcomes in animal models highlight the need for human clinical trials.
    • Further research in humans is crucial to ascertain CsG's therapeutic window.
    • Determining if CsG offers a superior safety or efficacy profile compared to CsA is the ultimate goal.